Cheng Yu

Dr. Cheng Yu

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MWMo Wang
Mo Wang
JLJiawei Liu
Jiawei Liu
MXMingjing Xia
Mingjing Xia
LYLibinghan Yin
Libinghan Yin
LZLing Zhang
Ling Zhang
CYCheng Yu
Cheng Yu

9 July 2024 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
BZBaochen Zhang
Baochen Zhang
MWMo Wang
Mo Wang
LSLi Sun
Li Sun
JLJiawei Liu
Jiawei Liu
LYLibinghan Yin
Libinghan Yin
CYCheng Yu
Cheng Yu

25 August 2022 in Frontiers in Pharmacology
Verified
Journal Article
Open access
JLJiawei Liu
Jiawei Liu
LZLing Zhang
Ling Zhang
JGJian Gao
Jian Gao
BZBaochen Zhang
Baochen Zhang
XLXiaoli Liu
Xiaoli Liu
CYCheng Yu
Cheng Yu
Background: Due to the constant mutation of virus and the lack of specific therapeutic drugs, the coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) still poses a huge threat to the health of people, especially those with underlying diseases. Therefore, drug discovery against the SARS-CoV-2 remains of great significance.Methods: With the main protease of virus as the inhibitor target, 9,614 genistein derivatives were virtually screened by LeDock and AutoDock Vina, and the top 20 compounds with highest normalized scores were obtained. Molecular dynamics simulations were carried out for studying interactions between these 20 compounds and the target protein. The drug-like properties, activity, and ADMET of these compounds were also evaluated by DruLiTo software or online server.Results: Twenty compounds, including compound 11, were screened by normalized molecular docking, which could bind to the target through multiple non-bonding interactions. Molecular dynamics simulation results showed that compounds 2, 4, 5, 11, 13, 14, 17, and 18 had the best binding force with the target protein of SARS-CoV-2, and the absolute values of binding free energies all exceeded 50 kJ/mol. The drug-likeness properties indicated that a variety of compounds including compound 11 were worthy of further study. The results of bioactivity score prediction found that compounds 11 and 12 had high inhibitory activities against protease, which indicated that these two compounds had the potential to be further developed as COVID-19 inhibitors. Finally, compound 11 showed excellent predictive ADMET properties including high absorption and low toxicity.Conclusion: These in silico work results show that the preferred compound 11 (ZINC000111282222), which exhibited strong binding to SARS-CoV-2 main protease, acceptable drug-like properties, protease inhibitory activity and ADMET properties, has great promise for further research as a potential therapeutic agent against COVID-19.

26 August 2025 in Bioorganic Chemistry
Verified
Journal Article
Closed access
SLShu-Rui Li
Shu-Rui Li
JYJia-Chen Yu
Jia-Chen Yu
CYCheng Yu
Cheng Yu
CZChenghe Zhou
Chenghe Zhou

25 June 2025 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
QLQian-Yue Li
Qian-Yue Li
JZJing Zhang
Jing Zhang
LDLe-Ping Dai
Le-Ping Dai
YTYi-Min Tan
Yi-Min Tan
WGWei-Wei Gao
Wei-Wei Gao
CZChenghe Zhou
Chenghe Zhou

25 November 2025 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MWMo Wang
Mo Wang
MLMengru Liu
Mengru Liu
LGLijie Gao
Lijie Gao
JLJiawei Liu
Jiawei Liu
XLXifu Liu
Xifu Liu
CYCheng Yu
Cheng Yu